Comparison of treatment and survival in European patients with GIST
Research type
Research Study
Full title
Comparison of treatment and survival in European patients with a gastrointestinal stromal tumor- EURECCA study
IRAS ID
269457
Contact name
Yvonne Schrage
Contact email
Sponsor organisation
Leiden University Medical Center
Clinicaltrials.gov Identifier
not applicable, not applicable
Duration of Study in the UK
0 years, 1 months, 30 days
Research summary
Gastrointestinal stromal tumors (GISTs) represent the most common sarcoma of the gastrointestinal tract. Despite this, they are rare tumors with an estimated incidence of 17 per million a year. Due to this rarity, most European studies are performed with limited number of patients or lack detailed data about important prognostic factors.
Because of the rarity of GIST, a standardized and international approach regarding management of GIST is necessary to improve the clinical outcomes. However, it is unknown whether variation exists in Europe with respect to the treatment strategies and outcome of GIST in these countries.The aim of this study is to describe and compare the treatment and (overall and relative) survival of patients diagnosed with GIST in European countries participating in the EURECCA consortium.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
19/WM/0237
Date of REC Opinion
25 Sep 2019
REC opinion
Further Information Favourable Opinion